Opioid agonist/antagonist combinations

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 7749542
APP PUB NO 20080292694A1
SERIAL NO

12220760

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The invention is directed in part to oral dosage forms comprising a combination of an orally analgesically effective amount of an opioid agonist and an orally active opioid antagonist, the opioid antagonist being included in a ratio to the opioid agonist to provide a combination product which is analgesically effective when the combination is administered orally, but which is aversive in a physically dependent subject. Preferably, the amount of opioid antagonist included in the combination product provides at least a mildly negative, “aversive” experience in physically dependent addicts (e.g., precipitated abstinence syndrome).

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddressTotal Patents
PURDUE PHARMA L.P.STAMFORD, CT449

International Classification(s)

  • [Classification Symbol]
  • [Patents Count]

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Colucci, Robert D Newtown, US 21 1843
Kaiko, Robert F Weston, US 47 3012

Cited Art Landscape

Patent Info (Count) # Cites Year
 
Other [Check patent profile for assignment information] (5)
5376662 Method of attenuating nerve injury induced pain 75 1993
2004/0092,542 Tamper-resistant oral opioid agonist formulations 56 2003
2005/0095,291 Tamper-resistant oral opioid agonist formulations 77 2003
2005/0181,046 Tamper-resistant oral opioid agonist formulations 70 2003
2006/0039,970 Tamper-resistant oral opioid agonist formulations 43 2003
 
NOVA PHARMACEUTICAL CORPORATION (2)
4760069 Oximes of oxymorphone, naltrexone and naloxone as potent, selective opioid receptor agonists and antagonists 89 1985
4889860 Oximes of oxymorphone, naltrexone and naloxone as potent, selective opioid receptor agonists and antagonists 97 1987
 
The Lynx Project Limited (1)
6310072 Production of analgesic synergy by co-administration of sub-analgesic doses of a MU opioid agonist and a kappa-2 opioid agonist 77 1997
 
VIRGINIA COMMONWEALTH UNIVERSITY (4)
5352683 Method for the treatment of chronic pain 129 1993
5321012 Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance 209 1993
5502058 Method for the treatment of pain 187 1994
5556838 Inhibiting the development of tolerance to and/or dependence on an addictive substance 185 1994
 
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (1)
5225440 Attenuation of the opioid withdrawal syndrome by inhibitors of nitric oxide synthase 82 1991
 
ELI LILLY AND COMPANY (1)
5998434 Composition for treating pain 68 1998
 
SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (1)
4803208 Opiate agonists and antagonists 77 1985
 
ICN HUNGARY RT. (1)
5317022 Pharmaceutical composition and use 80 1992
 
G. D. Searle & Co. (1)
5616601 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation 175 1995
 
SCULLY SCOTT MURPHY & PRESSER, PC (1)
5426112 Growth regulation and related applications of opioid antagonists 144 1993
 
BAKER NORTON PHARMACEUTICALS, INC. (1)
4873076 Method of safely providing anesthesia or conscious sedation 91 1989
 
OMEROS CORPORATION (2)
5858017 Urologic irrigation solution and method for inhibition of pain, inflammation and spasm 137 1996
5860950 Arthroscopic irrigation solution and method for inhibition of pain and inflammation 125 1996
 
COLMAN PRODUCTS LIMITED (1)
4935428 Treating opiate dependence 105 1988
 
THE ROCKEFELLER UNIVERSITY (3)
4987136 Method for controlling gastrointestinal dysmotility 150 1986
4769372 Method of treating patients suffering from chronic pain or chronic cough 177 1986
4785000 Method of treating patients suffering from chronic pain or chronic cough 124 1987
 
ADIR ET COMPAGNIE (1)
5130311 Oxazolopyridine compounds, compositions and use 103 1991
 
Schaap; Robert J. (2)
5316759 Agonist-antagonist combination to reduce the use of nicotine and other drugs 104 1992
5574052 Agonist-antagonist combination to reduce the use of nicotine and other drugs 166 1994
 
E. I. DU PONT DE NEMOURS AND COMPANY (2)
4451470 Analgesic, antagonist, and/or anorectic 14-fluoromorphinans 91 1982
5593994 Prostaglandin synthase inhibitors 122 1994
 
BRISTOL-MYERS SQUIBB COMPANY (1)
4457933 Prevention of analgesic abuse 198 1981
 
DynaGen, Inc. (1)
5486362 Controlled, sustained release delivery system for treating drug dependency 141 1993
 
MERCK SHARP & DOHME LTD. (1)
5880132 Tachykinin antagonist and an opioid analgesic effective at treating pain or nociception 81 1997
 
WARNER-LAMBERT COMPANY LLC (1)
5149538 Misuse-resistive transdermal opioid dosage form 258 1991
 
THE UNIVERSITY OF CHICAGO (4)
4719215 Quaternary derivatives of noroxymorphone which relieve nausea and emesis 122 1986
4861781 Quaternary derivatives of noroxymorphone which relieve nausea and emesis 116 1987
5102887 Method for reducing emesis and nausea induced by the administration of an emesis causing agent 115 1990
5972954 Use of methylnaltrexone and related compounds 133 1997
 
UNITED BIOMEDICAL, INC. (2)
5633259 Method for identification of low/non-addictive opioid analgesics and the use of said analgesics for treatment of opioid addiction 76 1995
5624932 Method for identification of low/non-addictive opioid analgesics and the use of said analgesics for treatment of opioid addiction 75 1995
 
UNIVERSITY OF OREGON (1)
5514680 Glycine receptor antagonists and the use thereof 122 1993
 
MERCK FROSST COMPANY (1)
5474995 Phenyl heterocycles as cox-2 inhibitors 218 1994
 
CONTRAL CLINICS OY (3)
4882335 Method for treating alcohol-drinking response 102 1988
5096715 Method and means for treating alcoholism by extinguishing the alcohol-drinking response using a transdermally administered opiate antagonist 85 1989
5086058 Method for treating alcoholism with nalmefene 98 1990
 
ALZA CORPORATION (4)
4573995 Transdermal therapeutic systems for the administration of naloxone, naltrexone and nalbuphine 182 1984
5236714 Abusable substance dosage form having reduced abuse potential 148 1988
5460826 Morphine therapy 165 1994
5866164 Composition and dosage form comprising opioid antagonist 271 1997
 
YOUNG, JACQUELINE, MS. (1)
5356900 Method of treating chronic herpes virus infections using an opiate receptor antagonist 79 1993
 
SIMON, DAVID L. (1)
6103258 Salts and bases of the 17-(Cyclopropylmethyl)-4,5 alpha-epoxy-6-Methylenemorphinan-3,14 diol molecule for optimizing dopamine homeostasis during administration of opioid analgesics 71 1998
 
MERCK FROSST CANADA LTD. (10)
5409944 Alkanesulfonamido-1-indanone derivatives as inhibitors of cyclooxygenase 127 1993
5604260 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2 146 1993
5436265 1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents 145 1993
5521213 Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2 153 1994
5552422 Aryl substituted 5,5 fused aromatic nitrogen compounds as anti-inflammatory agents 166 1995
5536752 Phenyl heterocycles as COX-2 inhibitors 143 1995
5550142 Phenyl heterocycles as cox-2 inhibitors 147 1995
5510368 N-benzyl-3-indoleacetic acids as antiinflammatory drugs 144 1995
5604253 N-benzylindol-3-yl propanoic acid derivatives as cyclooxygenase inhibitors 134 1995
5639780 N-benzyl indol-3-yl butanoic acid derivatives as cyclooxygenase inhibitors 134 1995
 
EURO-CELTIQUE S.A. (35)
4366310 Controlled release compositions 109 1980
4443428 Extended action controlled release compositions 173 1982
4940587 Oral pharmaceutical composition through mucosa 133 1986
4844907 Pharmaceutical composition comprising analgesic and anti-inflammatory agent 160 1986
4834965 Controlled release pharmaceutical composition 117 1987
4867985 Spheroids 110 1988
5071646 Pharmaceutical ion exchange resin composition 163 1989
5091189 Controlled release dosage forms having a defined water content 63 1991
5215758 Controlled release matrix suppository for pharmaceuticals 144 1991
5324351 Aqueous dispersions of zein and preparation thereof 170 1992
5356467 Controlled release coatings derived from aqueous dispersions of zein 272 1993
5500227 Immediate release tablet cores of insoluble drugs having sustained-release coating 243 1993
5622722 Spheroid formulation 65 1994
5508043 Controlled release matrix for pharmaceuticals 94 1995
5670172 Pharmaceutical spheroid formulation 113 1995
6024982 Immediate release tablet cores of insoluble drugs having sustained-release coating 166 1995
5811126 Controlled release matrix for pharmaceuticals 162 1995
5763452 Pharmaceutical compositions and usages 61 1996
5849240 Method of preparing sustained release pharmaceutical compositions 230 1996
5891471 Pharmaceutical multiparticulates 192 1996
5601845 Pharmaceutical spheroid formulation 112 1996
5843480 Controlled release diamorphine formulation 156 1996
5879705 Sustained release compositions of morphine and a method of preparing pharmaceutical compositions 197 1997
5908848 Synergistic composition of codine and ibuprofen to treat arthritis 63 1997
5942241 Formulations and methods for providing prolonged local anesthesia 184 1997
6068855 Pharmaceutical composition containing a fusible carrier and method for producing the same 104 1997
5965163 Substained release compositions and a method of preparing pharmaceutical compositions 203 1997
6077532 Pharmaceutical ion exchange resin composition 70 1998
6306438 Stabilized sustained release tramadol formulations 116 1998
6399096 Pharmaceutical formulation 119 1998
6143328 Sustained release compositions and a method of preparing pharmaceutical compositions 85 1999
6162467 Sustained release compositions and a method of preparing pharmaceutical compositions 166 1999
6210714 Immediate release tablet cores of acetaminophen having sustained-release coating 125 2000
6387404 Immediate release tablet cores of insoluble drugs having sustained-release coating 133 2001
6627635 Method of preventing abuse of opioid dosage forms 176 2001
 
PURDUE PHARMA L.P. (40)
4828836 Controlled release pharmaceutical composition 239 1987
4834985 Controlled release pharmaceutical composition 248 1987
4990341 Controlled release hydromorphone composition 218 1989
5266331 Controlled release oxycodone compositions 312 1991
5273760 Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer 312 1991
5286493 Stabilized controlled release formulations having acrylic polymer coating 308 1992
5549912 Controlled release oxycodone compositions 303 1993
5472712 Controlled-release formulations coated with aqueous dispersions of ethylcellulose 298 1993
5478577 Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level 320 1993
5411745 Powder-layered morphine sulfate formulations 200 1994
5965161 Extruded multi-particulates 249 1994
5639476 Controlled release formulations coated with aqueous dispersions of acrylic polymers 613 1995
5508042 Controlled release oxycodone compositions 340 1995
5968551 Orally administrable opioid formulations having extended duration of effect 330 1995
5958459 Opioid formulations having extended controlled released 220 1995
5656295 Controlled release oxycodone compositions 289 1996
5681585 Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer 179 1996
5672360 Method of treating pain by administering 24 hour oral opioid formulations 293 1996
6143322 Method of treating humans with opioid formulations having extended controlled release 217 1997
5958452 Extruded orally administrable opioid formulations 295 1997
5968547 Method of providing sustained analgesia with buprenorphine 124 1997
6077533 Powder-layered oral dosage forms 94 1998
6228863 Method of preventing abuse of opioid dosage forms 273 1998
* 6277384 Opioid agonist/antagonist combinations 170 1998
6103261 Opioid formulations having extended controlled release 205 1999
6335033 Melt-extrusion multiparticulates 157 1999
6261599 Melt-extruded orally administrable opioid formulations 228 1999
6294195 Orally administrable opioid formulations having extended duration of effect 186 1999
6375957 Opioid agonist/opioid antagonist/acetaminophen combinations 279 2000
6696088 Tamper-resistant oral opioid agonist formulations 227 2001
6716449 Controlled-release compositions containing opioid agonist and antagonist 130 2001
* 6475494 Opioid agonist/antagonist combinations 146 2001
2003/0069,263 Pharmaceutical combinations of oxycodone and naloxone 89 2002
2003/0073,714 Opioid agonist formulations with releasable and sequestered antagonist 87 2002
* 6696066 Opioid agonist/antagonist combinations 200 2002
2003/0229,111 Naltrexone hydrochloride compositions 42 2003
2004/0186,121 Tamper-resistant oral opioid agonist formulations 66 2003
* 7172767 Opioid agonist / antagonist combinations 117 2003
2006/0182,801 Sequestered antagonist formulations 79 2006
* 7419686 Opioid agonist/antagonist combinations 72 2006
 
EUROCELTIQUE S.A., 122, BOULEVARD DE LA PETRUSSE, LUXEMBOURG (2)
4844909 Controlled release hydromorphone composition 212 1987
4844910 Spheroids 73 1987
 
McGinnis; Carolyn (1)
4608376 Opiate agonists and antagonists 73 1982
 
AMINOTEK SCIENCES, INC. A CORP. OF NEW JERSEY (1)
5256669 Methods and compositions for treating acute or chronic pain and drug addiction 81 1992
 
UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (1)
4464378 Method of administering narcotic antagonists and analgesics and novel dosage forms containing same 234 1981
 
PEPTECH (UK) LIMITED (1)
5534492 Muramyl peptide for the treatment of toxicity 70 1995
 
The United States of America as represented by the Secretary of the Army (1)
5834477 Opiate analgesic formulation with improved safety 66 1994
 
ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (5)
5472943 Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other opioid agonists 169 1993
5585348 Use of excitatory opioid receptor antagonists to prevent growth factor-induced hyperalgesia 103 1993
* 5580876 Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists 119 1995
6194382 Method and composition for treating irritable bowel syndrome using low doses of opioid receptor antagonists 79 1999
6765010 Compositions and methods for enhancing analgesic potency of tramadol and attenuating its adverse side effects 67 2002
 
RECKITT BENCKISER HEALTHCARE (UK) LIMITED (2)
4582835 Analgesic compositions 162 1984
4661492 Analgesic compositions 130 1985
 
GENERAL ELECTRIC COMPANY (1)
5226331 Apparatus and method for measuring the particle number rate and the velocity distribution of a sprayed stream 49 1991
 
RUTGERS, STATE UNIVERSITY OF NEW JERSEY, THE, OLD QUEEN BUILDING, SOMERSET AND GEORGE STREETS, NEW BRUNSWICK, NJ 08903 (1)
4806341 Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration 204 1986
 
ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (6)
* 5512578 Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opiod agonists 132 1994
5767125 Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists 118 1996
6096756 Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists 149 1998
2001/0006,967 METHOD OF SIMULTANEOUSLY ENHANCING ANALGESIC POTENCY AND ATTENUATING ADVERSE SIDE EFFECTS CAUSED BY TRAMADOL AND OTHER BIMODALLY-ACTING OPIOID AGONISTS 55 1999
6362194 Method and simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists 68 2000
6395705 Method and composition for treating irritable bowel syndrome using low doses of opioid receptor antagonists 75 2001
 
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (1)
4806543 Method and compositions for reducing neurotoxic injury 100 1986
 
REGENTS OF THE UNIVERSITY OF MINNESOTA (6)
4401672 Non-addictive narcotic antitussive preparation 85 1981
4730048 Gut-selective opiates 117 1985
5352680 Delta opioid receptor antagonists to block opioid agonist tolerance and dependence 134 1992
5457208 Kappa opioid receptor antagonists 96 1993
5578725 Delta opioid receptor antagonists 79 1995
5780479 Use of opioid antagonists to treat impulse-control disorders 74 1997
 
THE MCLEAN HOSPITAL CORPORATION (1)
5075341 Treatment for cocaine abuse 170 1989
 
Ortho-McNeil Pharmaceutical, Inc. (1)
5336691 Composition comprising a tramadol material and acetaminophen and its use 108 1992
 
NAPP PHARMACEUTICAL GROUP LIMITED (3)
5591452 Controlled release formulation 120 1994
6326027 Controlled release formulation 114 1995
6254887 Controlled release tramadol 123 1996
 
ENCINAL PHARMACEUTICAL INVESTMENTS, LLC (1)
5869097 Method of therapy comprising an osmotic caplet 99 1992
 
PURDUE PHARMA COMPANY, THE (2)
4861598 Controlled release bases for pharmaceuticals 285 1986
4970075 Controlled release bases for pharmaceuticals 245 1989
 
DUPONT MERCK PHARMACEUTICAL COMPANY, THE (1)
4722928 N-oxide prodrug derivatives of 3-hydroxy morphinans and partial morphinans having improved oral bioavailability, pharmaceutical compositions, and processes 43 1985
 
PUREUE PHARMA L.P. (1)
4834984 Controlled release dihydrocodeine composition 200 1987
 
LIFESHIELD SCIENCES LLC (1)
2004/0158,312 Braided endoluminal device having tapered filaments 24 2003
 
BASF AKTIENGESELLSCHAFT (2)
4806558 Diarylacetylenes and their use in treating acne 75 1985
4957681 Preparation of pharmaceutical mixtures 171 1989
* Cited By Examiner

Patent Citation Ranking

Forward Cite Landscape

Patent Info (Count) # Cites Year
 
RECRO GAINESVILLE LLC (4)
9132096 Abuse resistant pharmaceutical compositions 2 2014
9486451 Abuse resistant pharmaceutical compositions 0 2015
9452163 Abuse resistant pharmaceutical compositions 0 2015
9713611 Abuse resistant pharmaceutical compositions 0 2016
 
BANNER LIFE SCIENCES LLC (1)
9861629 Opioid abuse deterrent dosage forms 0 2016
 
EURO-CELTIQUE S.A. (1)
9814710 Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome 0 2014
 
PURDUE PHARMA L.P. (29)
8518925 Opioids for the treatment of the chronic obstructive pulmonary disease (COPD) 6 2005
9101625 Buprenorphine-wafer for drug substitution therapy 1 2007
8987290 Use of opioid formulations in needle-less drug delivery devices 1 2007
* 2010/0056,554 USE OF OPIOID FORMULATIONS IN NEEDLE-LESS DRUG DELIVERY DEVICES 0 2007
9271940 Immediate release pharmaceutical compositions comprising oxycodone and naloxone 0 2010
* 8105631 Opioid agonist/antagonist combinations 46 2010
8673355 Opioid agonist/antagonist combinations 18 2011
8846090 Matrix for sustained, invariant and independent release of active compounds 20 2012
8822487 Opioid agonist/opioid antagonist/acetaminophen combinations 18 2012
8846091 Matrix for sustained, invariant and independent release of active compounds 19 2013
9084729 Abuse-resistant controlled-release opioid dosage form 4 2013
8969369 Abuse-resistant controlled-release opioid dosage form 19 2013
9056051 Abuse-resistant controlled-release opioid dosage form 6 2014
9205082 Opioid agonist/antagonist combinations 2 2014
9555000 Pharmaceutical preparation containing oxycodone and naloxone 1 2014
9474750 Opioid agonist/opioid antagonist/acetaminophen combinations 1 2014
9655855 Matrix for sustained, invariant and independent release of active compounds 1 2014
8936808 Opioid agonist/opioid antagonist/acetaminophen combinations 6 2014
8932630 Opioid agonist/antagonist combinations 6 2014
9168252 Abuse-resistant controlled-release opioid dosage form 3 2015
9161937 Abuse-resistant controlled-release opioid dosage form 4 2015
9283216 Abuse-resistant controlled-release opioid dosage form 1 2015
9283221 Abuse-resistant controlled-release opioid dosage form 1 2015
9820983 Immediate release pharmaceutical compositions comprising oxycodone and naloxone 0 2016
9358230 Abuse-resistant controlled-release opioid dosage form 1 2016
9345701 Abuse-resistant controlled-release opioid dosage form 1 2016
9763931 Buprenorphine-wafer for drug substitution therapy 0 2016
9511066 Abuse-resistant controlled-release opioid dosage form 1 2016
9480685 Abuse-resistant controlled-release opioid dosage form 1 2016
 
QRxPHARMA Ltd. (1)
* 8933092 Methods and compositions comprising sequential administration opioid receptor agonists 1 2012
 
RHODES PHARMACEUTICALS L.P. (2)
9370512 Buprenorphine-wafer for drug substitution therapy 1 2015
9861628 Buprenorphine-wafer for drug substitution therapy 0 2016
 
EGALET LTD. (10)
8877241 Morphine controlled release system 4 2004
9005660 Immediate release composition resistant to abuse by intake of alcohol 6 2010
9023394 Formulations and methods for the controlled release of active drug substances 4 2013
9694080 Polymer release system 0 2013
8808745 Morphine polymer release system 8 2013
9044402 Abuse-deterrent pharmaceutical compositions for controlled release 5 2014
9707179 Opioid polymer release system 0 2014
9642809 Controlled release pharmaceutical compositions for prolonged effect 0 2014
9375428 Morphine controlled release system 1 2014
9358295 Immediate release composition resistant to abuse by intake of alcohol 3 2015
* Cited By Examiner

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Jan 6, 2018
11.5 Year Payment $7400.00 $3700.00 $1850.00 Jan 6, 2022
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00